Background: Antidepressant medication adherence is among the most important problems in health care worldwide. Interventions designed to increase adherence have largely failed, pointing towards a critical need to better understand the underlying decision-making processes that contribute to adherence. A computational decision-making model that integrates empirical data with a fundamental action selection principle could be pragmatically useful in 1) making individual level predictions about adherence, and 2) providing an explanatory framework that improves our understanding of non-adherence.
Introduction
The efficacy of medical treatment depends crucially on a patient's decision to adhere to the treatment prescribed. Unfortunately, the number of patients who choose to follow treatment recommendations are quite low -despite the fact that treatment would often lead to significant improvement in their quality of life (1). By some estimates nearly half of all prescribed medications are not taken and roughly 125,000 deaths each year are due to non-adherence; costs associated with non-adherence are also estimated to be between $100 and $300 billion annually
(2). In the context of mental healthcare -which will be the focus of this paper -roughly one in five patients adhere to antidepressant medication treatment for more than four months (3), and the majority discontinue within the first 30 days (4). Low adherence rates also do not appear fully attributable to an objective lack of efficacy, as those who follow antidepressant treatment recommendations show lower levels of recurrence risk (5), cardiovascular mortality (6), overall mortality (7, 8) and lower suicide rates (9). Individuals who adhere to treatment also report greater perceived benefits and lower levels of medication-related concerns than those who do not adhere (1). Thus, it is somewhat perplexing that patients often choose not to adhere.
Major factors that can influence adherence decisions include patients' beliefs about medication and their personality attributes. For example, adherence to psychiatric interventions is lower in those with lower treatment expectancy (10) and in those who experience sexual side effects (11). These and other findings have led to the 'necessity-concerns framework' (12) which proposes that adherence decisions follow from weighing expected negative outcomes against beliefs about the necessity/efficacy of the treatment (13) (14) (15) (16) (17) (18) . Personality variables associated with greater adherence include higher persistence (19, 20) , greater self-efficacy (21-23), lower optimism (24), greater self-control (25), and a greater internal locus of control (26) (27) .
Habit formation -in which an action begins to occur more "automatically" (i.e., in the absence of explicitly expected future consequences) -may also be central to the development of stable health behaviors (28) , an effect that could generalize to adherence behavior (29, 30) .
However, studies have found that the amount of time required to form strong habits is highly variable from one individual to another (e.g., 18 to 254 days in one study (31) ). The processes that moderate habit formation time are therefore also highly relevant to understanding long-term adherence.
While several different interventions to promote adherence have been tested, involving educational (32, 33) counseling (34), and coaching (35) approaches, they have each shown little evidence of efficacy in randomized controlled trials (36) . There is therefore a clear need to better understand the decision-making processes contributing to adherence behavior. Such processes, if better characterized, could possibly help inform more targeted interventions as well as inspire the creation of better measures for predicting adherence.
In this manuscript our goal is to construct a computational model that can generate decisions to adhere or not adhere, and that provides a detailed characterization of several different probabilistic beliefs and related inference processes that plausibly contribute to these decisions.
Computational approaches, and those associated with computational psychiatry in particular (37-40), have gained prominence in recent years due in part to their potential to characterize such processes in a quantitative manner and to illustrate the way a number of underlying processes central to any decision-making system can contribute to maladaptive perception and behavior.
In what follows we introduce a specific computational model of antidepressant medication adherence, based on the active inference framework (41). The development of such a model may be crucial in clarifying the way that individual differences in computational processes can arbitrate between adherence and non-adherence in individual patients. We will focus on the initial decision to adhere over the first 12 weeks of treatment, in which symptoms typically decline and stabilize (42) and in which side effects first appear and subsequently reduce somewhat in severity (43). We will then simulate processes that may moderate the speed with which individuals can develop a strong medication-taking habit after their initial decision to
adhere.
An active inference model of adherence
According to the Active Inference model used here (41), the brain embodies a generative model that represents different possible states of the world and continuously generates predictions about the observations/outcomes it will receive from the internal/external environment if its beliefs are accurate. It then uses subsequent observations to update the model and to generate sequences of actions (policies) that are expected to minimize uncertainty and lead to the most preferred outcomes. This type of model (see figure 1 for more details) is formally known as a partially observable Markov decision process (MDP) and provides a particularly useful heuristic framework to examine alterations in decision processes due to altered affect-driven belief systems (44, 45) . The formal basis for Active Inference has been thoroughly detailed elsewhere (41, (46) (47) (48) (49) , and the interested reader is referred there for a full mathematical treatment.
In our model, the policy to adhere or cease adhering on (any day during) each of 12 weeks of treatment (13 policies total, formally modeled as one choice per week) is based on initial predictions about how observed depressive symptom severity (from 0-10) and side effect severity (from 0-3) will change over time given each possible choice, and on how these expectations are subsequently updated when actual changes in symptoms and side effects are observed. The possible states in our model correspond to beliefs about "perceived quality of life"
(which predict different combinations of observed depressive symptom and side effect levels), and beliefs about whether or not one is currently choosing to adhere (which predict different patterns of change over time in depressive symptom and side effect levels).
One must also specify several matrices in an MDP that define the probabilistic relationships between each of these variables; these include a matrix encoding the relationships between states and observations (A matrix), how states are expected to evolve over time (B matrix), the relative preference for some observations over others (C matrix), expectations about the initial states one will start out in (D matrix), and prior expectations about which actions one is most likely to choose in general (E matrix). For more detail about each of these variables and matrices, see table 1 and figure 1. Figure 1 . Illustration of the Markov decision process formulation of active inference used in the simulations described in this paper. The generative model is here depicted graphically on the right, such that arrows indicate dependencies between variables. Here observations (o) depend on hidden states (s), where this relationship is specified by the A matrix, and those states depend on both previous states (as specified by the B matrix, or the initial states specified by the D matrix) and the sequences of actions/policies (π) selected by the agent. The probability of selecting a particular policy in turn depends on the expected free energy (G) of each policy with respect to the prior preferences (C) of the agent. The degree to which expected free energy influences policy selection is also modulated by a prior policy precision parameter (γ), which is in turn dependent on beta (β) -where higher values of beta promote lower confidence in policy selection (i.e., less influence of the differences in expected free energy across policies). For more details regarding the associated mathematics, see (46, 50) . In our model, the observations were depression symptom levels and antidepressant side effects, the hidden states included beliefs about progress in treatment over time (i.e., improvements in quality of life) and beliefs about adherence decisions, and the policies included the choice to adhere or cease adherence at each week over 12 weeks of treatment (e.g., choosing to discontinue on a Wednesday vs. a Saturday of a given week was treated as the same choice in the model; as described in the main text, this modeling choice allowed the integration of week by week empirical data on symptom and side effect trajectories on antidepressants). As depicted on the left, our simulations began at "week 0" when treatment was initially recommended; the simulated patient then chose whether or not to adhere to treatment based on their beliefs about the way that symptoms and side effects would change over time if they did vs. did not adhere. Preferences were set such that the agent has stronger and stronger preferences to observe lower and lower symptom levels as well as lower and lower side effect levels.
In our model, the A-matrix was constructed such that steadily lowering (but fluctuating) symptom levels were generated for each week the agent continued to take the medication (based on the dose response time courses empirically characterized in a mega analysis of three SSRIs;
(42)). Specifically, Gaussian distributions were specified over a symptom severity scale from 0 to 10, with empirically based means that probabilistically decreased from baseline levels over the 1 st 6 weeks of treatment and then remained somewhat stable thereafter (i.e., depending on the standard deviations set for these distributions). The means were: 9. 36, 8.04, 6.91, 5.94, 5.10, 4.38, 3.77 . The medication taking action also generated moderate side effect levels in the first six weeks and mild side effect levels from weeks 7 to 12 (broadly based on the empirical antidepressant side effect time courses characterized in (43)). In contrast, the choice to cease taking the medication led to the cessation of side effects and a gradual return to baseline symptom levels.
The B-matrix was constructed so that agent controlled the transition from choosing to take the medication to choosing to cease the medication at each week (i.e., if two individuals ceased taking the medication on different days during the same week, these were formally treated as the same choice). Simultaneously, each action was associated with transitions toward increasing or decreasing perceived quality of life levels, respectively. The C-matrix was constructed such that the agent preferred the lowest symptom levels most (magnitudes from 0-10) and the lowest side effect severity most (magnitudes: 0, 2, 4, 6). The D-matrix was constructed such that the agent always began in an initial state of being "undecided" about choosing to adhere or not, and always began in an initial state of being at the lowest perceived quality of life. The E-matrix was initially set such that the agent had no bias (habit) for choosing to adhere or not adhere.
The parameters that characterize individual differences in our model are described in table 2. These correspond to differences in (beliefs about) the predictability and magnitude of changes in symptoms and side effects, how far into the future one considers when making decisions (policy depth), confidence in the consequences of choosing different actions (prior policy precision), and the strength of medication-taking habits. Figure 2 . (A) Displays the levels of hidden state factor 1 and 2 (treatment progress and adherence decisions) and their mapping to different lower-level representations of symptom levels and side effect severity (here modelled as outcomes). Each combination of levels in the two hidden state factors generated different observation patterns and state transitions with different probabilities. Red arrows correspond to the observations (and transitions) generated when the simulated patient chooses to continue medication, whereas blue arrows correspond to the observations (and transitions) generated when the patient chooses to discontinue medication (see text for details). Black arrows correspond to observations generated by hidden states that do not depend on the selection of one policy vs. another. Each of the six parameters in the model are also illustrated with a brief description (and described in the text in more detail). For example, symptom predictability was modulated by reducing the precision of the mapping from hidden state levels to symptom severity observations. Response magnitude was modulated by shifting the observable symptom severities toward lower or higher levels. Side effect severity was modulated by shifting the observable side effect levels to higher or lower values. For example, while in the figure it shows that moderate side effects are generated in the first six weeks of treatment and mild side effects are observed thereafter, this could be shifted such that they instead transition from severe to moderate, or from mild to none. See the text and tables for a thorough description of the other parameters. (B) Displays the A-matrices encoding the state-observation mappings under different parameter values (i.e., lighter colors indicate higher probabilities). (Top row) The precision of the first matrix (i.e., encoding beliefs about how precisely different "perceived quality of life levels" -corresponding to the amount of time on the medication -will lead to different observed symptom levels) could be adjusted via specifying the standard deviation of an associated Gaussian probability density function (SDs = 0.1, 1, 2, and 4 are shown here from left to right). (Middle row) Medication response magnitude could be modulated from (from left to right) strong, moderate, weak, and very weak responses, corresponding to incremental shifts upward and to the right in the same matrix. (Bottom row) The second matrix (i.e., encoding beliefs about how taking the medication will generate different side effect severities over time) could also be modulated to simulate the magnitude of side effect responses. From left to right, the patient either initially experience severe side effects that eventually settled at moderate levels, initially moderate levels of that eventually settled at mild levels, or initially mild levels that eventually resolved. The arrows indicating policy depth signify that those with greater policy depths will consider more distant predicted observations in decision-making.
Simulating individual differences in adherence

Initial simulations
The left panel of figure 3 illustrates an example simulation under one set of parameter values, in which policy depth was at its maximum value of 12, symptom predictability was high (SD = 0.01), symptom reductions were high (i.e., the agent was a "strong responder" to the drug), side effects were mild, policy precision was high (β = 1), and no medication-taking habit had been formed (the E-matrix distribution was flat over all policies). As can be seen, the agent chose to adhere and observed steady symptom reductions and some initial mild side effects that resolved after the first six weeks. The middle panel of figure 3 illustrates another example simulation in which symptom predictability was reduced (SD = 2) and side effects were severe. In this case, the agent chose not to adhere. In these simulations, the agent's expectations were consistent with its subsequent observations. The right panel of figure 3 illustrates a third example simulation in which the agent believed symptom predictability was higher than it really was (SD = 1 vs. 2) and side effects and symptom reductions were moderate (which the agent expected). In this case, the agent took the medication the first week, but then ceased taking the medication after observing an unexpected increase in symptom levels during the second week. Figure 3 . Example trials displaying different adherence decisions under different parameter values. In the top plots, cyan dots indicate the true action taken, and darker colors indicate higher levels of confidence in one action over others. In the middle and bottom plots, cyan does indicate observations, whereas darker colors indicate more strongly preferred observations. The top plots illustrate the choice to adhere or not adhere at each of the 12 weeks, the middle plots display observed symptoms over time with severities from 10 to 1, and the bottom plots illustrate observed side effects from mild to severe. Under the parameter values used in the left simulation, including mild side effects, strong symptom reductions, and high symptom predictability, the agent chose to adhere. Under the parameter values used in the middle simulation, in which symptom predictability was low and side effects were severe, the agent chose not to adhere -leading to an absence of side effects and symptoms continuing to fluctuate around baseline levels. Under the parameter values used in the right simulation, in which the agent expected symptoms to be more predictable than they actually were, the agent initially chooses to adhere but then stops when it observes an unexpected fluctuation upward and symptom intensity and a moderate increase in side effects. After ceasing medication, side effects resolve and symptoms continue to fluctuate around baseline levels. See the main text for more details about the parameter manipulations in each simulation.
Parameter interactions in the context of accurate expectations
To better characterize this parameter space, we repeated the simulations above at each of many combinations of parameter values. Figure 4 illustrates two example plots from part of this parameter space where the agent had accurate expectations, in which medication response magnitude and side effect severity were fixed at moderate levels. Here, the x-axis in each plot corresponds to symptom predictability (from low to high: i.e., SDs from 4 to 0.1), whereas the yaxis corresponds to policy depth (from 2 to 12 weeks). The plot on the left corresponds to an agent with low policy precision (β = 10), whereas the plot on the right corresponds to an agent with high policy precision (β = 1). Black squares in these plots correspond to agents that remained adherent all the way into week 12, whereas white squares indicate agents that ceased adherence prior to week 12. As can be seen, there is a clear boundary in which, below a certain policy depth and level of symptom predictability, adherence behavior ceases. Interestingly, adherence behavior increases across the space when policy precision is low. This suggests that, when one is not confident in policy selection (it is less clear that one policy will produce more preferred observations than others), one is more likely to adhere in an "exploratory" manner (e.g., "I don't think this will work, but who knows?"). Figure 4 . Two example plots from a larger parameter space with dimensions corresponding to different values for policy depth, symptom predictability, drug response magnitude, side effect severity, and policy precision. In these two plots the agent had accurate expectations about what it would observe under different policies, and medication response magnitude and side effect severity were fixed at moderate levels. The x-axis in each plot corresponds to symptom predictability (from low to high: i.e., SDs from 4 to 0.1), whereas the y-axis corresponds to policy depth (from 2 to 12 weeks). The plot on the left corresponds to an agent with low policy precision (β = 10), whereas the plot on the right corresponds to an agent with high policy precision (β = 1). Black squares in these plots correspond to agents that remained adherent all the way into week 12, whereas white squares indicate agents that ceased adherence prior to week 12. The main text for interpretation. Figure 5 provides a more complete depiction of this parameter space under different levels of medication response magnitudes (larger x-axis across plots, from very weak to strong response) and side effect severities (larger y-axis across plots, from low to high severity). As can be seen, under high side effect severity and low response magnitude, adherence does not occur 1 6
no matter the policy depth or symptom predictability (upper left plot), whereas adherence occurs fairly broadly when side effects are low and response magnitude is high (bottom left plot). Figure 5 . A more complete depiction the parameter space illustrated in figure 4 including different levels of medication response magnitudes (larger x-axis across plots, from very weak to strong response) and side effect severities (larger y-axis across plots, from low to high severity). See main text for interpretation.
Parameter interactions in the context of inaccurate expectations
Crucially, in the previous simulations it was assumed that the agent's beliefs about the effects of medication were accurate. However, a patient's beliefs need not match reality. As such, we then dissociated the agent's beliefs from the statistics of subsequent observations to see if the agent being surprised would influence adherence in interesting ways. Figure 6 One result is that, when observed symptom reductions are highly unreliable/noisy, the agent only remained adherent if her prior expectations very precisely predicted that they would be reliable. When observed symptom reductions were instead highly consistent/reliable, the agent surprisingly also chose to adhere when she expected symptom reductions to be highly unreliable. Thorough inspections of the parameter space confirmed that, in these cases of highly reliable or unreliable symptom reductions, there was little influence of policy precision, drug response magnitude, or side effect severity. Other interesting results were observable in cases of objectively moderate levels of symptom reduction reliability. For example, there appears to be a general effect in which adherence was higher when expectations about side effects matched the actual side effects observed. This effect was more pronounced in the case of objectively strong drug responses; in the case of objectively weak drug responses and severe side effects, adherence levels also became more dependent on the expected reliability of symptom reductions. In cases of objectively low side effects, adherence went up in general, most notably in cases of high policy depth and the belief that symptom reductions would be unreliable (unless expected side effects were severe).
The general finding that adherence is higher when expected observations about side effects are confirmed appears sensible, in that, if one initially chose to "try out" adherence based on one's expectations, non-preferred surprising observations would be more likely to "change one's mind" later. The finding that, in the context of objectively reliable symptom reductions, adherence occurs at low but not intermediate levels of expected symptom predictability is initially more surprising. However, when symptoms are expected to fluctuate very unreliably, it makes sense retrospectively that being "pleasantly surprised" that observations are more reliable than expected would promote adherence. In contrast, if one initially expects moderate predictability, the level of surprise may not be sufficient to change one's mind. Finally, it is fairly intuitive that, in the face of highly fluctuating symptoms, adherence would require a strong 0 counteracting belief that they would still be reliable at future time points (e.g., "it's been a bumpy ride to start, but I think things are going to stabilize soon").
Parameter interactions in the context of habit formation
To investigate why some individuals take much longer to form strong habits than others (as reviewed in the introduction), we ran a final set of simulations in which we manipulated the strength of our simulated agent's habit to take medication. We manipulated the E-matrix in the model so as to simulate the effect of an agent having observed herself take medication different numbers of times (i.e., 1, 15, 30, and 60 previous medication-taking decisions). We also gave the agent a policy depth of 1, such that she was not forward-looking beyond the immediate expected consequences of adhering. As can be seen in figure 7, different simulated agents begin to adhere habitually after different lengths of time depending on several of the other parameter values manipulated in the simulations described previously. Longer time periods of previous adherence lead to habitual adherence. Habits also took longer to develop when expected drug responses were low and unpredictable, and when expected side effect severity was high (i.e., the medication-taking "impulse" less effectively competed against explicit planning when strongly non-preferred or unpredictable outcomes were expected to occur immediately). Low policy precision also led to much faster habit formation. Psychologically, this might be interpreted as indicating an interesting (and somewhat paradoxical) predicted effect. That is, in the context of higher side effects and lower drug responses, individuals who are less confident in decisionmaking should actually be more likely to adhere long-term than those who confidently predict at treatment onset that the drug will not be very helpful. Figure 7 . A depiction of the influence of habit formation at different habit strengths, based on the previous number of times (e.g., days) that an individual has chosen to take the medication previously, under different values for the other parameters in the model. Habit formation was modeled via manipulation of the E-matrix by increasing the probability, in terms of counts (i.e., 1, 15, 30, and 60 previous medication-taking decisions), of the medication-taking action relative to other allowable actions.
Here the agent also had a policy depth of 1, such that she was not forward-looking beyond the immediate expected consequences of adhering. The agent otherwise had accurate expectations about the observations it would make under different actions. See main text for interpretation.
Discussion
We have used simulations to quantitatively demonstrate a number of distinct decisionmaking processes that could contribute to individual differences in adherence behavior. At least three important research implications follow. First, it will be an important task to either identify or design simple measures (e.g., that could be administered in a clinic) capable of characterizing where an individual patient falls within the parameter space we have described.
Such measures could potentially improve advanced prediction of who will and will not adhere.
With respect to existing measures, the values for some parameters might be assessed by those used within the "necessity versus concerns" framework, such as the Beliefs about Medicines Questionnaire (12) or the revised Medication Adherence Reasons Scale (51) -perhaps most plausibly the parameters associated with beliefs about the magnitude of symptom reductions and side effects. In table 3, we have also listed a number of example self-report items that, based on the model we have described (and straightforward extensions of it), could be useful for gathering information about a patient's adherence-relevant beliefs. Once in a validated form, this type of questionnaire could be tested for its utility in predicting adherence behavior in advance.
The values of other parameters, in contrast, might be informed by personality measures.
For example, the behavior associated with the personality variables of persistence (20) and locus of control (26) could follow from a combination of beliefs in high future predictability and high policy precision (and likely preferences with strong magnitudes as well). Low self-efficacy (21) could instead follow from a combination of low policy precision and precise expectations for non-preferred outcomes (while optimism may correspond to precise expectations for preferred outcomes, perhaps with or without taking medication -which could explain why more optimistic individuals are less likely to adhere; (24)). This is speculative, however, and will need to be examined in future work.
A second implication is that it will be important within the field of computational psychiatry to attempt to develop tasks, or find ways of acquiring detailed adherence behavior data, that could be used in conjunction with a formal model (such as the one we described above)
to explicitly fit to patient behavior. This would potentially allow for a more detailed and informative way to phenotype decision-making processes within individual patients. It should be mentioned, however, that this may be challenging due to the fact that the behavior in question involves simple binary decisions. That is, if multiple parameter value combinations can produce the exact same behavior, this prevents identification of unique parameter values that best explain individual patients' behavior. As such, this endeavor will likely require use of very detailed behavioral data, perhaps involving day by day medication-taking actions.
A third implication pertains to the need for effective adherence-promoting interventions.
As reviewed above, current interventions have met with limited success (36) to specific values, and the simulation results would be expected to differ somewhat if different values had been chosen. In principle, simulations could also have been run at different values for this parameter, which would have led to an even higher dimensional space than we have presented. We also did not manipulate beliefs about the predictability of side effects, which could also plausibly influence adherence decisions. In these cases, we instead chose to hold these factors fixed and examine the effect of altering the dynamics of observed symptoms/side effect levels over time on versus off treatment.
There may also be additional factors that were not modeled explicitly, but that could be simulated within the model we have presented (and in principle be used in characterizing patients' decisions). For example, some individuals may simply forget to take their medication a couple of times and then cease altogether (51). In our model, this could be captured in part by low policy precision (i.e., increasing randomness in behavior), but would need to be combined with other factors such as the belief that all progress has been lost (as could be encoded within the individual's transition beliefs [B-matrix]). As another example, some people might cease medication after experiencing symptom improvement because they expect such improvements to remain stable after ceasing to take the drug (and the belief that side effects would go away). This could also be captured in our model with straightforward adjustments to the B-matrix.
Such limitations aside, we believe our model represents an important first step in gaining a more detailed understanding of the underlying factors and dynamics that influence a patient's decision to follow medical treatment recommendations. Because of the model's generality, it can also be very easily extended to model adherence to other medications, simply by inserting the symptom reduction and side effect profiles that characterize those medications. For example, it 6
follows from the general model structure that adherence to immediately rewarding medications (e.g. benzodiazepines) would be high and promote fast habit information, but behavior would also be influenced by the same parameters used here to investigate antidepressant adherence. The next steps in using these models will require identifying means of empirically characterizing and intervening on these mechanisms in an individualized manner.
Software note
Although the generative model -specified by the various matrices described in this paperchanges from application to application, the belief updates are generic and can be implemented 
